Where BioXcel Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 8 analysts have published their opinion on BioXcel Therapeutics (NASDAQ:BTAI) stock, with 6 bullish and 2 indifferent ratings. The average 12-month price target is $51.25, with a high of $79.00 and a low of $22.00. The average price target has increased by 19.19% over the past month.
May 26, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioXcel Therapeutics has received 6 bullish and 2 indifferent ratings from 8 analysts over the past 3 months. The average 12-month price target is $51.25, up 19.19% in the past month.
The majority of analysts have a bullish outlook on BioXcel Therapeutics, with 6 out of 8 giving positive ratings. The average 12-month price target has increased by 19.19% over the past month, indicating a positive sentiment towards the stock. This could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100